Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PDE9A | O76083 | 14/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22042833 | 0.86 | PDE9A (0.52) | ESR1PDE9AALDH1A1TSHR | |
| SCHEMBL22042948 | 0.82 | CYP1A2 (0.67) | L3MBTL1PDE9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL22042903 | 0.78 | LMNA (0.51) | LMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL19342087 | 0.77 | DAPK3 (0.61) | L3MBTL1PDE9ATSHR | |
| SCHEMBL22072396 | 0.76 | LMNA (0.57) | LMNAESR1L3MBTL1PDE9ASMN1; SMN2 | |
| SCHEMBL22042945 | 0.76 | RAB9A (0.52) | LMNAL3MBTL1PDE9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15745833 | 0.76 | PDE9A (0.54) | PDE9A | |
| SCHEMBL16981646 | 0.76 | PDE9A (0.58) | PDE9A | |
| SCHEMBL22071795 | 0.75 | ALDH1A1 (0.82) | LMNAESR1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19342102 | 0.75 | MEN1 (0.69) | LMNAPDE9AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020116972-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |